To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Congress Publications
For Information on past and upcoming Medical Congresses in which argenx is presenting clincial research and data, please select the disease area of interest
Myasthenia Gravis
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
Posters
- Achievement of Minimal Symptom Expression in Participants Treated With Efgartigimod in ADAPT+ and ADAPT-SC+
- COVID-19 Vaccination Response in Participants Receiving Efgartigimod IV or Efgartigimod PH20 SC in ADAPT+ or ADAPT-SC+
- Efficacy and Safety of Efgartigimod IV and PH20 SC in gMG: Analysis of AChR-Ab− Participants in ADAPT+/ADAPT-SC+
- Efgartigimod Consistently Improved Health-Related Quality of Life in AChR-Ab+ Participants With gMG in IV and SC Trials
- Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalised Myasthenia Gravis: Part A of ADAPT NXT
- Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20: Interim Results of the ADAPT-SC+ Trial
- Real world reduction in oral corticosteroid utilization following efgartigimod initiation
- Safety Profile of Intravenous Efgartigimod From Clinical Trials in Immunoglobulin G–Mediated Autoimmune Diseases
- Steroid toxicity in adults with myasthenia gravis in the United States based on electronic health records
- Subcutaneous Efgartigimod PH20 Demonstrates Improvements in gMG Patients Regardless of Prior Administration Route
- Clinical Outcomes, Disease Course, and Health-Related Quality of Life in PatientsWith Multifocal Motor Neuropathy: iMMersioN, Study in Progress
Oral Presentations
- Safety Profile of Subcutaneous Efgartigimod PH20 From Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases
- Efficacy and Safety of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy: Results of ADHERE/ADHERE+
- Empasiprubart (ARGX-117) in Multifocal Motor Neuropathy: Initial Safety and Efficacy Data of the Phase 2 ARDA Study
Japanese Society of Neurology (JSN)
May 28 - 31, 2024
-
Tokyo, Japan
Japanese Society of Neurology (JSN)
May 28 - 31, 2024
-
Tokyo, Japan
Oral Presentations
Canadian Neurological Sciences Federation (CNSF)
May 19 - 25, 2024
-
Toronto, ON, Canada
Canadian Neurological Sciences Federation (CNSF)
May 19 - 25, 2024
-
Toronto, ON, Canada
Posters
Oral Presentations
- Cost-effectiveness analysis of efgartigimod versus chronic intravenous immunoglobulin (IVIg) for treatment of acetylcholine receptor antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) in Canada
- Efficacy, Safety, and Tolerability of Subcutaneous Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy: Results From the ADHERE Trial
American Academy of Neurology (AAN)
April 4 - 8, 2025
-
Denver, CO
American Academy of Neurology (AAN)
April 4 - 8, 2025
-
Denver, CO
Posters
- Changes in Nonsteroidal Immunosuppressive Treatment Usage Before and After Efgartigimod Initiation in Patients With Myasthenia Gravis
- Combined Analyses of Participants With Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated With Efgartigimod Across Clinical Studies
- COVID-19 Vaccination Response in Participants Across Clinical Trials Investigating Efgartigimod in Autoimmune Diseases
- Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis
- First-in-Human Dose Selection and Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase
- Hospitalization Outcomes After Efgartigimod Initiation in Patients With Myasthenia Gravis
- Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe
- Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
- Network Meta-Analysis of Treatment Options in Generalized Myasthenia Gravis: Evaluating the Comparative Effectiveness of Emerging Immunomodulatory Therapies
- Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody-Negative Generalized Myasthenia Gravis
- Study Design of Subcutaneous Efgartigimod PH20 in Juvenile Generalized Myasthenia Gravis
- Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT
- Transition From Intravenous Immunoglobulin to Efgartigimod PH20 SC in Participants With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 4 Study in Progress
- Treatment Impact of Efgartigimod PH20 SC on I-RODS Daily Activity Assessment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Post Hoc Analysis of the Registrational ADHERE Study
Muscular Dystrophy Association (MDA)
March 15 - 18, 2025
-
Orlando, FL
Muscular Dystrophy Association (MDA)
March 15 - 18, 2025
-
Orlando, FL
Posters
- Employment, daily activities and caregiver burden in CIDP: results of a real-world US survey
- Incremental economic and clinical burden of illness among adults with chronic inflammatory demyelinating polyneuropathy in the United States
- Magnitude of Response With Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE_ADHERE+ Trials
- Study Design of Subcutaneous Efgartigimod PH20 in Juvenile Generalized Myasthenia Gravis
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multifocal Motor Neuropathy (MMN)
2025 Peripheral Nerve Society (PNS) Annual Meeting
May 15 - 18, 2025
2025 Peripheral Nerve Society (PNS) Annual Meeting
May 15 - 18, 2025
Posters
- ADHERE+ Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy
- Autoantibody Signatures in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Insights on Glycolipid Reactivity From the ADHERE Trial
- Baseline Characteristics of the First 100 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study
- Burden of Disease in Multifocal Motor Neuropathy: A Global Quantitative Survey of Patients
- Efgartigimod in Pretreated CIDP With Persistent Disease Activity or Progressive-Relapsing Active Disease: ADHERE Analysis
- Empasiprubart in Multifocal Motor Neuropathy: Safety and Efficacy Data From the Phase 2 ARDA Study
- Empasiprubart Versus Intravenous Immunoglobulin in Multifocal Motor Neuropathy Phase 3 Study Design: EMPASSION
- Impact of Efgartigimod PH20 SC on Autoimmunity Biomarkers in the ADHERE Trial: Exploratory Analyses
- Impact of Prior Chronic Inflammatory Demyelinating Polyneuropathy Treatments in the ADHERE Trial Post Hoc Analyses
- Intravenous Immunoglobulin to Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 4 Study in Progress
- Management of Patients With Multifocal Motor Neuropathy: A Global Quantitative Survey of Neurologists
Annual Meeting of the American Neurological Association (ANA)
September 13 - 16, 2024
Annual Meeting of the American Neurological Association (ANA)
September 13 - 16, 2024
Posters
The Neuromuscular Study Group (NMSG) Annual Scientific Meeting
September 19 - 21, 2024
The Neuromuscular Study Group (NMSG) Annual Scientific Meeting
September 19 - 21, 2024
Posters
- Clinical Outcomes Disease Course and QoL in Patients With Multifocal Motor Neuropathy iMMersioN Study in Progress
- Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Chronic Inflammatory Demyelinating Polyneuropathy Results of ADHEREADHERE+
- Empasiprubart (ARGX-117) in Multifocal Motor Neuropathy_Initial Safety and Efficacy Data of the Phase 2 ARDA Study
- Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis_Part A of ADAPT NXT
- Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
- Tapering of Corticosteroids in Patients With Generalized Myasthenia Gravis Treated With Efgartigimod A Case Series
Presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting
October 14 - 17, 2024
Presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting
October 14 - 17, 2024
Posters
- Clinical Outcomes, Disease Course, and Quality of Life in Patients With MultifocalMotor Neuropathy iMMersioN, Study in Progress
- Combined Analyses of Participants With Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated With Efgartigimod Across Clinical Studies
- COVID-19 Vaccination Response in Participants Receiving Efgartigimod IV or Efgartigimod PH20 SC in ADAPT+ or ADAPT-SC+
- Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE Trial Subgroup Analysis
- Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy ADHEREADHERE+ Trials
- Empasiprubart (ARGX-117) in Multifocal Motor Neuropathy Initial Safety and Efficacy Data of the Phase 2 ARDA Study
- Empasiprubart(ARGX-117) in Multifocal Motor Neuropathy Baseline Characteristics and MMN Confirmation Committee Outcomes of the Phase 2 ARDA Stud
- Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT
- Heterogeneity of EQ-5D-5L utilities among people suffering from CIDP
- Long-Term Safety and Efficacy of Efgartigimod PH20 SC in Generalized Myasthenia Gravis Interim Analysis of Anti-Acetylcholine Receptor Antibody
- Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants With Generalized Myasthenia Gravis Interim Result
- Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
- Real-World Reduction in Oral Glucocorticoid Utilization at 1-Year Following Efgartigimod Initiation
- Risk of Serious Infections and Malignancies in Adult Myasthenia Gravis Patients A US Claims Database Study
- Safety Profile of Intravenous Efgartigimod From Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases
- Safety Profile of Subcutaneous Efgartigimod PH20 From Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases
- Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Patients With Amyotrophic Lateral Sclerosis A Phase 2a Study
- Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Participants With DOK7 Congenital Myasthenic Syndromes Phase
- Steroid Toxicity in Adults With Myasthenia Gravis in the United States Based on Electronic Health Records
- Steroid Use, Toxicity, and Monitoring in Patients With Chronic Inflammatory Demyelinating Polyneuropathy A Survey of Neurologists in the United
- Steroid Use, Toxicity, and Monitoring in Patients With Generalized Myasthenia Gravis A Survey of Neurologists in the United States
- Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy Key Secondary Outcomes From the ADHERE Trial
- The Burden people suffering from CIDP experience In terms of Utilities Comparison With The General Population
Myasthenia Gravis Foundation of America (MGFA) 15th International Conference on Myasthenia Gravis and Related Disorders
May 12 - 14, 2025
Myasthenia Gravis Foundation of America (MGFA) 15th International Conference on Myasthenia Gravis and Related Disorders
May 12 - 14, 2025
Posters
- Assessing Efgartigimod Dosing Patterns and Myasthenia Gravis Activities of Daily Living Outcomes in Clinical Practice: Results from a Large Patient Support Program Database in the United States
- Combined Analyses of Participants Treated With Efgartigimod Early in the Course of Generalized Myasthenia Gravis Across Clinical Studies
- Combined Analyses of Participants With Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated With Efgartigimod Across Clinical Studies
- COVID-19 Vaccination Response in Participants Across Clinical Trials Investigating Efgartigimod in Autoimmune Diseases
- Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis
- Effect of Intravenous and Subcutaneous Efgartigimod on MG-ADL and QMG Subdomains in the ADAPT-SC Study in Participants With Generalized Myasthenia Gravis
- First-in-Human Dose Selection and Pharmacokinetics, Safety, Tolerability, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase
- Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe
- Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
- Network Meta-Analysis of Treatment Options in Generalized Myasthenia Gravis: Evaluating the Comparative Effectiveness of Emerging Immunomodulatory Therapies
- Observed Efficacy of Efgartigimod in Generalized Myasthenia Gravis Across Patient Subgroups in the ADAPT-SC+ Study
- Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
- Real-World Reduction in Oral Corticosteroid Utilization at 1-Year Following Efgartigimod Initiation
- Structure-function analysis of ARGX-119, a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase
- Study Design of Subcutaneous Efgartigimod PH20 in Juvenile Generalized Myasthenia Gravis
- Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part B of ADAPT NXT
EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY (EULAR)
June 10 - 13, 2025
EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY (EULAR)
June 10 - 13, 2025
Posters
- Efficacy and Safety of Efgartigimod PH20 Subcutaneous by Prefilled Syringe in Adults With Primary Sjogren’s Disease: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With Open-Label Extension (UNITY)
- Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis (EMPACIFIC): A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study
Oral Presentations
- Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy Phase 2 Results From the ALKIVIA Study
- Treatment of Primary Sjogren’s Disease by Blocking FcRn Clinical and Translational Data From RHO, a Phase 2 Randomized, Placebo Controlled, Double-Blind, Proof-of-Concept Study With Efgartigimod
AANEM 2025
December 31, 2029
AANEM 2025
December 31, 2029
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2025 argenx MED-US-NON-2400036 V4 11/2025. All Rights Reserved.